Resources

A reliable supply chain is often referred to as the “backbone” of a health system. In addition to meeting the demand for drugs and medical supplies, it serves to safeguard a country’s investments in health commodities, which is particularly important as countries ramp up efforts to work toward universal health coverage.The aim of this Journey of the Pill assessment is to identify strengths and inefficiencies in the noncommunicable disease (NCD) supply chain in Vietnam. It builds on previous NCD supply chain assessments conducted in Ghana, Kenya, and Senegal. Further defining the journey of medicines will help inform the Ministry of Health and other stakeholders of future actions to strengthen commodity security for NCDs.

Training and competency assessment tool for users of the STANDARD G6PD Test

Examples of patient G6PD counseling cards

Before the COVID-19 pandemic, important progress had been made in improving maternal, neonatal, and child health (MCH) outcomes around the globe, with under-five deaths and maternal mortality falling to historic lows by 2019. However, the onset of the COVID-19 pandemic and resulting mortality has wreaked havoc on broad health outcomes.Over the last two years, PATH has worked alongside governments, donors, and partners around the globe to respond to COVID-19 while working to mitigate its impact by preserving the delivery of essential health services. In early 2022, we conducted an internal analysis to explore COVID-19 disruptions–with a special focus on the impact to MCH essential services–and the innovations that were deployed to address these disruptions. We found that despite reduced budgets for MCH, overstretched workforces, and a reduced focus on universal health care, governments and their partners developed and used a range of innovations at the primary health care (PHC) level intended to safeguard MCH care.Read PATH's full set of recommendations for USAID maternal and child health programming below.

The primary objective of this review is to summarize and assess the current evidence that could support a change to a single-dose schedule of HPV vaccine. The review also aims to identify gaps that remain in determining whether a single dose could be sufficiently protective to have a major impact against HPV infection and its sequelae, within the context of immunization programs. See also the companion resources:General summary (five pages)Technical synthesis (30 pages), of immunogenicity, efficacy, and effectiveness, forthcoming evidence, and areas for future research.Visit the Single-Dose HPV Vaccine Evaluation Consortium page for additional resources.